Audited Financial Results for the Quarter and Year ended March 31, 2026

Ebitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

JUBLINGREA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹732.00

prior close

₹728.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-4.2% vs market

Specialty Chemicals peers, median of 91sector-0.4%-3.6% vs sector

On the reaction day the stock moved 4.2 pts less than Nifty Smallcap 250 and 3.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-3.7

15m

-5.5

30m

-3.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0+0.2-4.2-0.4-3.6

Next day

-6.7+0.7-7.5-0.3-6.4

-11.2+0.1-11.3-1.2-10.0

-12.9-0.7-12.2-2.3-10.6

-12.8-0.2-12.7-1.5-11.3

-13.9-0.1-13.8-2.2-11.7

-14.3+0.5-14.8-2.1-12.2

15d

-11.3+3.1-14.3+0.0-11.3

-16.5+3.8-20.3+0.0-16.5

+1.8+5.0-3.2+3.2-1.5

-3.0+8.7-11.7+4.5-7.5

UpDownMarket · Nifty Smallcap 250Sector · Specialty Chemicals peers, median of 91Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Ingrevia reported consolidated revenue from operations of ₹4,38,807 lakhs for FY2026, up about 5% from ₹4,17,761 lakhs in FY2025. Net profit grew to ₹27,791 lakhs from ₹25,117 lakhs, a rise of roughly 10.6%. Operating margin improved to 8.92% (vs 8.65%) and net profit margin to 6.28% (vs 5.96%). Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on both standalone and consolidated results. An exceptional item of ₹1,304 lakhs was charged due to one-time impact of new Indian Labour Codes (effective November 2025). The company also completed acquisition of Remidex Pharma Private Limited during the quarter and recommended a total dividend of ₹5 per share (₹7,964 lakhs for full year).

Likely market impact

Positive results with margin expansion and profit growth; clean audit with no qualifications is reassuring for investors. The labour code one-time charge is non-recurring and properly separated.